Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Endothelin antagonism with bosentan: a review of potential applications
Autore:
Roux, S; Breu, V; Ertel, SI; Clozel, M;
Indirizzi:
Actel Ltd, Innovat Ctr, CH-4123 Allschwil, Switzerland Actel Ltd Allschwil Switzerland CH-4123 , CH-4123 Allschwil, Switzerland F Hoffmann La Roche & Co Ltd, CH-4070 Basel, Switzerland F Hoffmann La Roche & Co Ltd Basel Switzerland CH-4070 asel, Switzerland Sundgau Med Writers, F-68440 Habsheim, France Sundgau Med Writers Habsheim France F-68440 rs, F-68440 Habsheim, France
Titolo Testata:
JOURNAL OF MOLECULAR MEDICINE-JMM
fascicolo: 4, volume: 77, anno: 1999,
pagine: 364 - 376
SICI:
0946-2716(199904)77:4<364:EAWBAR>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
SPONTANEOUSLY HYPERTENSIVE RATS; CHRONIC HEART-FAILURE; B-RECEPTOR ANTAGONIST; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; EXPERIMENTAL CEREBRAL VASOSPASM; INCREASED PLASMA ENDOTHELIN-1; CONVERTING ENZYME-INHIBITION; SMOOTH-MUSCLE CELLS; ET(B) RECEPTORS; PULMONARY-HYPERTENSION;
Keywords:
bosentan; endothelin; endothelin receptors;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
180
Recensione:
Indirizzi per estratti:
Indirizzo: Clozel, M Actel Ltd, Innovat Ctr, Gewerbestr 16, CH-4123 Allschwil, Switzerland Actel Ltd Gewerbestr 16 Allschwil Switzerland CH-4123 itzerland
Citazione:
S. Roux et al., "Endothelin antagonism with bosentan: a review of potential applications", J MOL MED-J, 77(4), 1999, pp. 364-376

Abstract

Endothelin receptor antagonists have been proposed for the treatment of a variety of disorders in which the endothelins may act as pathogenic mediators, such as congestive heart failure, systemic and pulmonary hypertension, and cerebral vasospasm. Bosentan (Ro 47-0203) is a nonpeptide competitive antagonist, which can be a good tool for studying the endothelin system because it may be administered either acutely or chronically It is specific forthe endothelin system and blocks the actions of endothelin at both mammalian receptors (A and B), In experimental models of heart failure bosentan acts as a vasodilator and neurohormonal blocker that improves overall left ventricular performance and reduces renal dysfunction. Furthermore, in chronic studies, bosentan attenuates cardiac remodeling and significantly improves survival. In patients with chronic heart failure bosentan produces pulmonary and systemic vasodilation and may enhance conventional treatment with angiotensin-converting enzyme inhibitors. Long-term studies are being conducted to characterize the full therapeutic potential of bosentan in chronic heart failure. In experimental models bosentan reverses established pulmonary hypertension. Preclinical efficacy has also been demonstrated in essential hypertension, where bosentan can reduce blood pressure and end-organ damage. Clinical trials in hypertensive patients indicate that bosentan reducesblood pressure without heart rate increase or neurohumoral stimulation. finally, bosentan is being considered for the treatment of cerebral vasospasmfollowing subarachnoid hemorrhage, Bosentan reverses experimentally induced vasospasm of the basilar artery, and preliminary trials indicate that it can increase cerebral blood flow after aneurysmal subarachnoid hemorrhage.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 05:41:26